pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$TPSTTempest Therapeutics, Inc.

$TPST
Brisbane, CA, USupdated 3mo ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Preclinical: 1Phase 1: 1Phase 2: 1
1Preclinical1Phase 11Phase 2
Phase 2
amezalpat
Metastatic Hepatocellular Carcinoma (HCC)
Phase 1
TPST-1495
Adenocarcinoma Of The Gastroesophageal Junction
Preclinical
TPST-3003
Refractory Multiple Myeloma

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase1Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumorscompletedn=89
  • phase3A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapynot yet recruitingn=740
  • phase1TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancerscompletedn=38
🐶 Hiring Signal
No open roles indexed yet — view Tempest Therapeutics, Inc. jobs →

News

  • 9 biotechs will cut at least half their California workforces
    Workforce reductions have hit over 1,000 biopharma employees in The Golden State year to date, with pink slips coming from small biotechs and large pharmas. Biotechs have been hit the hardest, with…
    biospace · 1d ago
  • An eye drug biotech banks $118M and stocks its executive suite
    Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.
    biopharma_dive · 3mo ago
identifiers
ticker
$TPST
SEC CIK
0001544227
country
US
source
sec_tickers
top tags
Oncology3Colorectal Cancer1NSCLC1
mentioned in
2news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 8m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?